Functional Technologies Corp.
TSX VENTURE : FEB

Functional Technologies Corp.

January 24, 2011 09:00 ET

Functional Technologies Appoints Officer

VANCOUVER, BRITISH COLUMBIA--(Marketwire - Jan. 24, 2011) - Functional Technologies Corp. (TSX VENTURE:FEB) has appointed Dr. Connie Chen to the position of Vice President, Corporate Development and Communications. Dr. Chen's responsibilities will include defining and managing Functional Technologies' communications strategies and investor relations initiatives. 

Prior to joining Functional Technologies, Dr. Chen was a respected Biotechnology and Health Sciences Analyst at Loewen, Ondaatje and McCutcheon Limited, with more than five years experience in small-to-mid cap biotech equity research at independent Canadian investment banks. Dr. Chen holds a PhD in Pharmaceutical Sciences from the University of Toronto, with a focus in carcinogenesis and reproductive toxicology.

"I am pleased to being joining Functional Technologies at this exciting time in its development," said Dr. Chen. "I have been aware of the Company's technologies and business approach for a period of time, and look forward to working with the experienced management team in building shareholder value."

"We are pleased to appoint Dr. Connie Chen to the position of Vice President, Corporate Development and Communications. Connie's background and training give her the unique ability to complement our management team on a variety of key initiatives in both technology pipeline analysis and strategic development, as well as market-side communications and awareness building as we execute on commercializing our product pipeline moving forward," remarked CEO Howard Louie.

Dr. Chen has been granted an initial stock option for the purchase of 75,000 common shares at a price of $0.62 per share, exercisable for a period of five years. 

About Functional Technologies Corp.

Functional Technologies develops and commercializes proprietary technologies that enhance the natural properties of yeast and algae -- nature's microscopic workhorses. Our scientists apply novel techniques to these micro-celled organisms to resolve significant health and quality problems, and generate new opportunities in the global food, beverage and healthcare industries. Our first commercial products are the Phyterra™ line of proprietary yeast strains, designed to reduce the formation of foul-smelling hydrogen sulphide and the carcinogen urethane in wines and other fermented products. With a head office in Vancouver, Functional Technologies Corp. has R&D facilities in Prince Edward Island and a U.S. sales office in Napa Valley, California. For more information, please visit www.functionaltechcorp.com.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURRACY OF THIS RELEASE.

Contact Information

  • Functional Technologies Corp.
    Connie Chen
    VP, Corporate Development and Communications
    +1.647.271.1269
    www.functionaltechcorp.com